Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

Analysis of Long-term (Investment) Activity Ratios 

Microsoft Excel

Long-term Activity Ratios (Summary)

Gilead Sciences Inc., long-term (investment) activity ratios

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net fixed asset turnover 5.28 5.07 4.93 5.27 4.90
Net fixed asset turnover (including operating lease, right-of-use asset) 4.83 4.57 4.51 4.77 4.34
Total asset turnover 0.48 0.43 0.43 0.40 0.36
Equity turnover 1.48 1.18 1.27 1.28 1.34

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Gilead Sciences Inc. net fixed asset turnover ratio improved from 2022 to 2023 and from 2023 to 2024.
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Gilead Sciences Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) improved from 2022 to 2023 and from 2023 to 2024.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Gilead Sciences Inc. total asset turnover ratio improved from 2022 to 2023 and from 2023 to 2024.
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Gilead Sciences Inc. equity turnover ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level.

Net Fixed Asset Turnover

Gilead Sciences Inc., net fixed asset turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Product sales 28,610 26,934 26,982 27,008 24,355
Property, plant and equipment, net 5,414 5,317 5,475 5,121 4,967
Long-term Activity Ratio
Net fixed asset turnover1 5.28 5.07 4.93 5.27 4.90
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc. 10.97 10.89 11.76 11.00 8.73
Amgen Inc. 4.89 4.53 4.57 4.69 4.96
Bristol-Myers Squibb Co. 6.77 6.77 7.38 7.67 7.22
Danaher Corp. 4.78 5.25 7.96 7.77 6.83
Eli Lilly & Co. 2.63 2.64 2.81 3.15 2.83
Johnson & Johnson 4.33 4.28 4.79 4.95 4.40
Merck & Co. Inc. 2.70 2.61 2.77 2.53 2.67
Pfizer Inc. 3.46 3.14 6.22 5.52 3.07
Regeneron Pharmaceuticals Inc. 3.09 3.16 3.23 4.62 2.64
Thermo Fisher Scientific Inc. 4.61 4.54 4.84 4.71 5.45
Vertex Pharmaceuticals Inc. 8.98 8.51 8.06 6.92 6.47
Net Fixed Asset Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 4.18 4.12 4.98 4.98 4.31
Net Fixed Asset Turnover, Industry
Health Care 8.88 8.80 9.32 9.09 8.34

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Net fixed asset turnover = Product sales ÷ Property, plant and equipment, net
= 28,610 ÷ 5,414 = 5.28

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Gilead Sciences Inc. net fixed asset turnover ratio improved from 2022 to 2023 and from 2023 to 2024.

Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)

Gilead Sciences Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Product sales 28,610 26,934 26,982 27,008 24,355
 
Property, plant and equipment, net 5,414 5,317 5,475 5,121 4,967
Operating lease right-of-use assets, net (classified as Other long-term assets) 515 581 505 542 646
Property, plant and equipment, net (including operating lease, right-of-use asset) 5,929 5,898 5,980 5,663 5,613
Long-term Activity Ratio
Net fixed asset turnover (including operating lease, right-of-use asset)1 4.83 4.57 4.51 4.77 4.34
Benchmarks
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2
AbbVie Inc. 9.62 9.47 10.24 9.57 7.46
Amgen Inc. 4.51 4.08 4.13 4.23 4.58
Bristol-Myers Squibb Co. 5.78 5.60 6.18 6.66 6.30
Danaher Corp. 3.93 4.26 6.35 6.10 5.30
Eli Lilly & Co. 2.48 2.45 2.63 2.93 2.63
Johnson & Johnson 4.11 4.07 4.54 4.72 4.18
Merck & Co. Inc. 2.55 2.45 2.60 2.33 2.43
Pfizer Inc. 3.08 2.72 5.25 4.64 2.79
Regeneron Pharmaceuticals Inc. 2.95 3.11 3.17 4.52 2.58
Thermo Fisher Scientific Inc. 3.97 3.89 4.13 3.98 4.82
Vertex Pharmaceuticals Inc. 4.26 6.79 6.13 5.32 4.83
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Sector
Pharmaceuticals, Biotechnology & Life Sciences 3.78 3.71 4.48 4.45 3.91
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Industry
Health Care 7.33 7.17 7.48 7.17 6.51

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Product sales ÷ Property, plant and equipment, net (including operating lease, right-of-use asset)
= 28,610 ÷ 5,929 = 4.83

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Gilead Sciences Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) improved from 2022 to 2023 and from 2023 to 2024.

Total Asset Turnover

Gilead Sciences Inc., total asset turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Product sales 28,610 26,934 26,982 27,008 24,355
Total assets 58,995 62,125 63,171 67,952 68,407
Long-term Activity Ratio
Total asset turnover1 0.48 0.43 0.43 0.40 0.36
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc. 0.42 0.40 0.42 0.38 0.30
Amgen Inc. 0.35 0.28 0.38 0.40 0.39
Bristol-Myers Squibb Co. 0.52 0.47 0.48 0.42 0.36
Danaher Corp. 0.31 0.28 0.37 0.35 0.29
Eli Lilly & Co. 0.57 0.53 0.58 0.58 0.53
Johnson & Johnson 0.49 0.51 0.51 0.52 0.47
Merck & Co. Inc. 0.55 0.56 0.54 0.46 0.52
Pfizer Inc. 0.30 0.26 0.51 0.45 0.28
Regeneron Pharmaceuticals Inc. 0.38 0.40 0.42 0.63 0.50
Thermo Fisher Scientific Inc. 0.44 0.43 0.46 0.41 0.47
Vertex Pharmaceuticals Inc. 0.49 0.43 0.49 0.56 0.53
Total Asset Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 0.43 0.40 0.47 0.45 0.39
Total Asset Turnover, Industry
Health Care 0.75 0.73 0.75 0.70 0.64

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Total asset turnover = Product sales ÷ Total assets
= 28,610 ÷ 58,995 = 0.48

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Gilead Sciences Inc. total asset turnover ratio improved from 2022 to 2023 and from 2023 to 2024.

Equity Turnover

Gilead Sciences Inc., equity turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Product sales 28,610 26,934 26,982 27,008 24,355
Total Gilead stockholders’ equity 19,330 22,833 21,240 21,069 18,202
Long-term Activity Ratio
Equity turnover1 1.48 1.18 1.27 1.28 1.34
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc. 16.94 5.24 3.36 3.65 3.50
Amgen Inc. 5.45 4.32 6.77 3.63 2.58
Bristol-Myers Squibb Co. 2.96 1.53 1.49 1.29 1.12
Danaher Corp. 0.48 0.45 0.63 0.65 0.56
Eli Lilly & Co. 3.17 3.17 2.68 3.15 4.35
Johnson & Johnson 1.24 1.24 1.24 1.27 1.31
Merck & Co. Inc. 1.39 1.60 1.29 1.28 1.90
Pfizer Inc. 0.72 0.67 1.06 1.06 0.67
Regeneron Pharmaceuticals Inc. 0.48 0.51 0.54 0.86 0.77
Thermo Fisher Scientific Inc. 0.86 0.92 1.02 0.96 0.93
Vertex Pharmaceuticals Inc. 0.67 0.56 0.64 0.75 0.71
Equity Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 1.27 1.15 1.24 1.27 1.22
Equity Turnover, Industry
Health Care 2.10 2.00 1.97 1.91 1.89

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Equity turnover = Product sales ÷ Total Gilead stockholders’ equity
= 28,610 ÷ 19,330 = 1.48

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Gilead Sciences Inc. equity turnover ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level.